BioCryst Pharmaceuticals, Inc. (BCRX) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

BioCryst Pharmaceuticals, Inc. (BCRX) closed at USD 8.02 on 2026-10-15, a change of +9.7 % over the past year, with a market capitalization of USD 1.99B.

BioCryst Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BioCryst Pharmaceuticals, Inc. key figures

Previous close

USD 8.02 (2026-10-15)

1-year change

+9.7 %

Market cap

USD 1.99B

Enterprise value

USD 2.47B

P/E ratio (trailing)

-5.56

P/E ratio (forward)

8.29

EPS (trailing)

-1.40

EPS (forward)

0.94

PEG ratio

9.39

Price to book

-4.38

Revenue growth

33.6 %

Earnings growth

1,400 %

Dividend per share (trailing)

0.00

Short ratio

5.15

Employees

435

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BioCryst Pharmaceuticals, Inc. and compare it with other stocks.